1L. S. Freudenberg,G. Antoch,P. Schütt,T. Beyer,W. Jentzen,S. P. Müller,R. G?rges,M. R. Nowrousian,A. Bockisch,J. F. Debatin.FDG-PET/CT in re-staging of patients with lymphoma[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2004 (3)
2Allen-Auerbach M,Weber WA.Measuring response withFDG-PET:methodological aspects. The Oncologist . 2009
3Elstrom R,Guan I,Baker G,et al.Utility of FDG-PETscanning in lymphoma by WHO classification. Blood . 2003
4LeBlanc AK,Jakoby BW,Townsend DW,et al.18FDG-PET imaging in canine lymphoma and cutaneous mast celltumor. Veterinary Radiology and Ultrasound . 2009
5Rebollo Aguirre AC,Ramos-Font C,Villegas Portero R,et al.18F-fluorodeoxiglucose positron emission tomographyfor the evaluation of neoadjuvant therapy response inesophageal cancer:systematic review of the literature. Annals of Surgery . 2009
6Lowe VJ,Wiseman GA.Assessment of lymphoma therapyusing 18F-FDG PET. The Journal of Nuclear Medicine . 2002
7Terezakis SA,Hunt MA,Schmidtlein CR,et al.18FDG-PET with CT scanco-registration for radiation treatment planning of lymphoma patients. I J Radiat Oncol . 2007
8Schoder H,Meta J,Yap C,et al.Effect of whole-body 18F FDG PET imaging od clinical staging and management of patients with malignant lymphoma. The Journal of Nuclear Medicine . 2001
9Shen YY,Kao A,Yen RJ,et al.Comparison of18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67citrate scintigraphy for detecting malignant lymphoma. Oncology Reports . 2002
10M Allen-Auerbach,A Quon,WA Weber.Comparison between 2-deoxy-2-[(18)F]Fluoro-D-glucose positron-emission tomography and positron-emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Molecular Imaging and Biology . 2004
2Muhammad Wasif Saif, Ifigenia Tzannou, Nektaria Makrilia,Kostas Syrigos. Role and Cost Effectiveness of PET/CT in Management of Patients with Cancer. Yale Journal of Biology And Medicine ,2010,83:53-65.
3Cerci J J, Trindade E, Buccheri V, et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions[ J ]. Clin Lymphoma Myeloma Leuk, 2011,11(4) :314-320.
4Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and de- velopments [ J ]. Leuk Lymphoma, 2007,48 (2) :270-282.
5Jerusalem G, Hustinx R, Beguin Y, et al. Evaluation of therapy for lymphoma [ J ]. Semin Nucl Med, 2005,35 ( 3 ) : 186-196.
6Crocchiolo R, Fallanca F, Giovacchini G, et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of pa- tients with Hodgkin's lymphoma [ J ]. Ann Hematol, 2009,88 (12) : 1229-1236.
7Baba S, Abe K, Isoda T, et al. Impact of FDG-PET/CT in the management of lymphoma [ J ]. Ann Nucl Med, 2011,29 (10) :Epub ahead of print.
8Hutchings M, Barrington S F. PET/CT for therapy response assessment in lymphoma [ J ]. J Nucl Med, 2009,50 ( Suppl 1 ) :21-30.
9Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18) F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma[J]. Ann Oneol, 2002,13(9) :1356-1363.
10Juweid M E. FDG-PET/CT in lymphoma[J]. Methods Mol Biol, 2011,727(4) :1-19.
